lifestyle spending accounts glp-1 prescriptions weight management reimbursement Nutritional priorities to support therapy for obesity: A joint advisory from the American College of Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society Apaly Health Inc. Unveils Apaly

Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes

Expert Opinion on Pharmacotherapy, 21(11), 13191328

3 Works cited FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize, accessed February 2, 2026, Semaglutide Shortage Resolved McDermott Will & Schulte, accessed February 2, 2026, GLP-1 Update: Court Backs FDA in Tirzepatide Compounding Case, accessed February 2, 2026, The Return of 503B Compounding of GLP-1 Medications Frier Levitt, accessed February 2, 2026, The Strategic Imperative of Pharmaceutical Competitor Analysis: A Comprehensive Guide for 2026 and Beyond DrugPatentWatch, accessed February 2, 2026, Maximizing ROI on Drug Development by Monitoring Competitive Patent Portfolios, accessed February 2, 2026, Compounded Drug Products That Are Essentially Copies of Approved Drug Products Under Section 503B of the Federal Food, Drug, and Cosmetic Act FDA, accessed February 2, 2026, GLP-1 Weight-Loss Drugs Off Shortage List

According to researchers from Johns Hopkins, women who take GLP-1 RAs lose an average of 11% of their starting weight after 43 weeks of treatment